We are live on ! Find out more
Perceptive Advisors

Perceptive Advisors Portfolio holdings

AUM $5.74B Turnover 38.06%
1-Year Est. Return 183.85%
 

Perceptive Advisors is a life sciences investment firm whose flagship Perceptive Life Sciences Fund puts most of its money into publicly traded small and mid-sized companies. Joseph Edelman, a former senior analyst at Paramount Capital's Aries Fund, a biotechnology hedge fund, founded the firm in 1999. It launched its first credit fund in 2013, and in 2019 teamed up with the biotech startup accelerator Xontogeny to launch its first venture capital fund.

This Fund
S&P 500
This Quarter Est. Return
-1.22%
1 Year Est. Return
+183.85%
3 Year Est. Return
+1,392.3%
5 Year Est. Return
+3,239.37%
10 Year Est. Return
+33,396.11%
AUM
$5.74B
AUM Growth
-$922M
Cap. Flow
-$726M
Cap. Flow %
-12.65%
Top 10 Hldgs %
49.66%
Holding
134
New
25
Increased
15
Reduced
43
Closed
26
Avg Time Held Equity + Options
1.3 years
Top 10 Avg Time Held Equity + Options
0.8 years
Top 20 Avg Time Held Equity + Options
0.8 years
Avg Time Held Equity only
1.4 years
Top 10 Avg Time Held Equity only
0.8 years
Top 20 Avg Time Held Equity only
0.8 years

Top Buys

Rank Stock Value
1
FRNM icon
Freenome
FRNM
+$173M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$59.3M
3
WAT icon
Waters
WAT
+$54.1M
4
IRD icon
Opus Genetics
IRD
+$37.4M
5
ABT icon
Abbott
ABT
+$36M

Top Sells

Rank Stock Value
1
NUVL icon
Nuvalent
NUVL
+$195M
2
APGE icon
Apogee Therapeutics
APGE
+$174M
3
SYRE icon
Spyre Therapeutics
SYRE
+$100M
4
ROIV icon
Roivant Sciences
ROIV
+$57.1M
5
BIIB icon
Biogen
BIIB
+$52.6M

Sector Composition

Rank Sector Weight
1 Healthcare 92.62%
2 Miscellaneous 7.23%
3 Financials 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
PHAT icon
126
Phathom Pharmaceuticals
PHAT
$447M
– –
-532,000
Closed -$5.77M –
SRZNW icon
127
DELISTED
Surrozen Inc Warrant
SRZNW
– –
-166,666
Closed -$2.75K –
TENX icon
128
Tenax Therapeutics
TENX
$64.7M
– –
-1,700,000
Closed -$24.7M –
TWST icon
129
Twist Bioscience
TWST
$7.43B
– –
-36,812
Closed -$3.79M –
CTNM icon
130
Contineum Therapeutics
CTNM
$375M
– –
-1,255,592
Closed -$20.6M –
SION icon
131
Sionna Therapeutics
SION
$139M
– –
-905,000
Closed -$39.8M –
OMDA icon
132
Omada Health
OMDA
$873M
– –
-786,330
Closed -$17.3M –
RACC icon
133
Research Alliance Corp III
RACC
$92.1M
– –
-750,000
Closed -$8.02M –

Similar funds

Perceptive Advisors's Q3 2026 Portfolio in Review

As of Q3 2026, Perceptive Advisors held 134 positions worth $5.74B, down 14% from $6.66B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors withdrew a net $726M in Q3 2026, closing 26 positions and reducing 43 holdings. Its most notable exit was Nuvalent, an estimated $195M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 96% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Perceptive Advisors opened a new position in Freenome worth $199M.

  • Perceptive Advisors's largest Q3 2026 buy was Freenome: 12,606,053 shares worth $199M.
  • Perceptive Advisors added most to Amylyx Pharmaceuticals in Q3 2026, an estimated $59.3M increase.
  • Perceptive Advisors's biggest Q3 2026 reduction was Spyre Therapeutics, cutting an estimated $100M.
  • Perceptive Advisors fully exited Nuvalent in Q3 2026, selling an estimated $195M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $5.74B portfolio in Q3 2026.
  • Perceptive Advisors opened 25 new positions and closed 26 in Q3 2026.
  • Perceptive Advisors's portfolio value fell 14% quarter-over-quarter to $5.74B.

Based on Perceptive Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.